Dr. Grogan was a pathologist and professor at the University of Arizona when in the mid 1980’s he and a small team set out to challenge the limitations of the then current standards and processes for cancer pathology.  What was to become the company’s first digital pathology instrument evolved from Grogan’s notes on a yellow pad into the BenchMark IHC/ISH staining platforms.   Under Grogan’s leadership, Ventana was founded in 1987, went public in 1996, and was acquired by Roche for $3.4 billion in 2008. Over the last 25 years, Ventana has grown to become a global leader in developing and manufacturing tissue-based diagnostic instruments and tests focused on the detection of cancer. Ventana employees continue to pursue the same deeply rooted mission of innovating diagnostic testing and enabling personalized healthcare to improve the lives of all patients afflicted with cancer worldwide.

Dr. Grogan has made it his personal mission to make life better for the millions of patients who battle cancer each day.  His passion and dedication are infectious and has spread across the company that he and his team built. Through their efforts they have revolutionized the field of cancer diagnostics and are pioneering new roads in the field of personalized healthcare.”